| Drug Name |
Brinzolamide |
| Drug ID |
BADD_D00296 |
| Description |
Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. |
| Indications and Usage |
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. |
| Marketing Status |
approved |
| ATC Code |
S01EC04 |
| DrugBank ID |
DB01194
|
| KEGG ID |
D00652
|
| MeSH ID |
C111827
|
| PubChem ID |
68844
|
| TTD Drug ID |
D01MUR
|
| NDC Product Code |
40700-0072; 55718-165; 0078-0722; 14445-010; 65727-033; 68682-464; 58032-2011; 62009-0906; 63190-0280; 68108-0821; 58567-101; 82019-0001; 0591-2127; 0781-6014; 62207-011; 24208-464; 63629-8793; 63190-0400 |
| UNII |
9451Z89515
|
| Synonyms |
brinzolamide | (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-E)-1,2-thiazine-6-sulfonamide 1,1-dioxide | Azopt |
